Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MTA”

844 trials

Showing 20 of 844 results

Testing effectiveness (Phase 2)Study completedNCT00684099
What this trial is testing

Docetaxel/Pemetrexed as 1st Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung Cancer
Hellenic Oncology Research Group 70
Early research (Phase 1)Ended earlyNCT02309892
What this trial is testing

A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Helix BioPharma Corporation 14
Testing effectiveness (Phase 2)Study completedNCT04245085
What this trial is testing

ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma

Who this might be right for
EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
ETOP IBCSG Partners Foundation 95
Testing effectiveness (Phase 2)Study completedNCT00867009
What this trial is testing

Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Cancer
Eli Lilly and Company 113
Large-scale testing (Phase 3)Study completedNCT02864251
What this trial is testing

Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Who this might be right for
Non-Small-Cell Lung Carcinoma
Bristol-Myers Squibb 367
Testing effectiveness (Phase 2)Study completedNCT00269152
What this trial is testing

Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Eli Lilly and Company 122
Early research (Phase 1)Study completedNCT00034463
What this trial is testing

ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer

Who this might be right for
MetastasesCancer
Eli Lilly and Company
Large-scale testing (Phase 3)Study completedNCT00961415
What this trial is testing

AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 376
Early research (Phase 1)Active Not RecruitingNCT04162015
What this trial is testing

Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma

Who this might be right for
Malignant Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center 22
Large-scale testing (Phase 3)Study completedNCT01631136
What this trial is testing

Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer

Who this might be right for
Advanced Non Small Cell Lung Cancer
Intergroupe Francophone de Cancerologie Thoracique 932
Testing effectiveness (Phase 2)Study completedNCT00191308
What this trial is testing

Molecular Profiling in Lung Cancer Patients

Who this might be right for
Non-Small Cell Lung CancerCarcinoma
Eli Lilly and Company 30
Testing effectiveness (Phase 2)UnknownNCT01969955
What this trial is testing

Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer

Who this might be right for
Squamous Cell Carcinoma of Lung
Chinese Academy of Medical Sciences 50
Large-scale testing (Phase 3)Not Yet RecruitingNCT06380348
What this trial is testing

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Who this might be right for
Local Advanced or Metastatic NSCLC
Shanghai JMT-Bio Inc. 398
Large-scale testing (Phase 3)Active Not RecruitingNCT07207382
What this trial is testing

Clinical and Radiographic Evaluation of Three Biomimetic Materials in Pulp Therapy of Immature Young Permanent Teeth "A Randomized Controlled Clinical Trial"

Who this might be right for
Pulpotomy of Young Permanent Molars
Ain Shams University 69
Testing effectiveness (Phase 2)Study completedNCT00087113
What this trial is testing

Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix

Who this might be right for
Cervical Cancer
Gynecologic Oncology Group
Large-scale testing (Phase 3)Study completedNCT00363415
What this trial is testing

Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer

Who this might be right for
Small Cell Lung Cancer
Eli Lilly and Company 908
Large-scale testing (Phase 3)Ended earlyNCT01041781
What this trial is testing

Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Alliance for Clinical Trials in Oncology 313
Large-scale testing (Phase 3)UnknownNCT03924050
What this trial is testing

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Who this might be right for
Non-small Cell Lung Cancer
Shanghai Junshi Bioscience Co., Ltd. 440
Testing effectiveness (Phase 2)Study completedNCT02049060
What this trial is testing

Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin

Who this might be right for
Malignant Pleural MesotheliomaNonsquamous Nonsmall Cell Neoplasm of Lung
Armando Santoro, MD 31
Testing effectiveness (Phase 2)Looking for participantsNCT06772623
What this trial is testing

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Who this might be right for
Non Small Cell Lung Carcinoma
AbbVie 252
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation